Topical cyclosporine for severe dry eye disease in liver-transplanted Portuguese patients with familial amyloidotic polyneuropathy (ATTRV30M).
PURPOSE. Evaluation of the use of topical cyclosporine eyedrops in the treatment of severe dry eye disease in liver transplanted patients with familial amyloidotic polyneuropathy (FAP) unresponsive to therapy with artificial tears and lacrimal plugs.


METHODS
A prospective clinical study of 5 patients (10 eyes) admitted to the Ophthalmology Department of the Centro Hospitalar do Porto with severe dry eye disease refractory to artificial tears and lacrimal plug treatments. Evaluation of the patients included best-corrected visual acuity, corneal punctuate fluorescein staining, tear break-up time, Schirmer test without anesthesia, and Ocular Surface Disease Index. Patients were observed at time 0, and at 3, 7, and 11 months.


RESULTS
Treatment with topical cyclosporine improved all studied parameters from baseline, and in all the patients (p<0.001). The safety profile was excellent, without topical or systemic adverse events.


CONCLUSIONS
Topical cyclosporine was beneficial in the treatment of severe dry eye disease in liver transplanted patients with FAP.
Ophthalmology, Hospital de Santo António, Porto, Portugal; and Unidade Clínica de Paramiloidose, Hospital de Santo António, Porto, Portugal.
João M
JM
Beirão
Maria E
ME
Matos
Idalina B
IB
Beirão
Paulo P
PP
Costa
Paulo A
PA
Torres
D000287:Administration, Topical; D000328:Adult; D000682:Amyloid / Q000235:genetics; D028227:Amyloid Neuropathies, Familial / Q000453:epidemiology / Q000235:genetics / Q000601:surgery*; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D019793:Fluorescein / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007638:Keratoconjunctivitis Sicca / Q000188:drug therapy* / Q000503:physiopathology; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011174:Portugal / Q000453:epidemiology; D011228:Prealbumin / Q000235:genetics; D011446:Prospective Studies; D013194:Staining and Labeling; D013666:Tears / Q000502:physiology; D014792:Visual Acuity / Q000502:physiology
D000682:Amyloid; D007166:Immunosuppressive Agents; D009883:Ophthalmic Solutions; D011228:Prealbumin; D016572:Cyclosporine; C041120:amyloid prealbumin; D019793:Fluorescein